Renata Limited, the country's 4th largest pharmaceutical company, has secured a place on the prestigious list of Asia's 200 Best Under A Billion.
The annual Best Under A Billion list highlights 200 publicly listed small and mid sized companies in the Asia-Pacific region with sales under $1 billion and consistent top- and bottom-line growth.
According to Forbes, these companies, selected from 18,000 small and mid-sized companies, have track records of exceptional corporate performance.
Forbes Asia Best Under A Billion Virtual Forum and Awards Ceremony was held on November 23 from Singapore to celebrate the success.
The companies on this list have scored above their peers in a composite ranking that includes sales and profit growth, low debt levels and robust governance.
The criteria also ensured a geographic diversity of companies from across the region. By using metrics both quantitative and qualitative, the final list of 200 is truly a select group.
However, there is one Covid-19 caveat: The list is based on full-year data as of July 7 and does not fully reflect the impact from the pandemic-led downturn.
Renata Limited, formerly known as Pfizer Limited, is one of the fastest growing pharmaceutical and animal health product companies in Bangladesh. The company started its operations in 1972 as Pfizer (Bangladesh) Limited. In 1993, Pfizer transferred the ownership of its Bangladesh operations to local shareholders and the name of the company was changed to Renata Limited.
The Company is listed on the Dhaka Stock Exchange with a market capitalization of over USD $1 billion.
It has ten manufacturing facilities spread over three manufacturing sites while the product distribution is carried out by 19 depots across the country. Renata employs over 8,000 people.
Renata products are exported to Afghanistan, Belize, Cambodia, Ethiopia, Guyana, Honduras, Hong Kong, Kenya, Malaysia, Myanmar, Nepal, Philippines, Sri Lanka, Thailand, United Kingdom, and Vietnam.